Pharmaceutical Continuous Manufacturing Market Analysis 2031
药品连续制造市场规模预计将从 2023 年的 20.8 亿美元增至 2031 年的 46.7 亿美元。预计 2023-2031 年该市场的复合年增长率为 10.6%。监管机构的支持不断增加、合同制造商和内部制造商越来越多地采用药品制造程序以及与连续制造相关的优势可能仍然是市场的主要趋势。
制药连续制造市场分析
制药公司不断投资创新制造技术,以获得竞争优势并保持市场领先地位,从而推动连续制造市场的发展。连续生产使制药公司能够更好地控制其生产过程,这有助于提高最终产品的质量和一致性,从而减少偏差和浪费,并节省返工时间和召回成本。药品连续生产可以提高最终产品的质量、增强过程控制并允许实时释放测试。欧洲药品管理局 (EMA) 和美国食品药品监督管理局 (FDA) 是越来越支持在制药行业使用连续生产的监管机构。此外,由于通过自动化、系统控制、数据分析和过程分析技术 (PAT) 等手段提供了改进的过程监控、控制和优化,连续制造在制药行业变得更具吸引力和实用性,从而推动了市场的发展。 。
制药连续制造市场概述
作为一种可行的解决方案,可以最大限度地减少压力、减少药物开发时间和成本,同时保持最终产品的质量和供应,连续生产在制药行业得到了广泛的应用。因此,由于这些好处,连续制造市场正在健康增长。此外,美国食品和药物管理局 (FDA) 不断推出的促进连续药品制造系统使用的举措以及连续制造系统相对于批量制造的众多优势是推动市场增长的一些主要因素。然而,另一方面,药品连续制造系统的高成本实施可能会阻碍市场增长。
定制研究以满足您的要求
我们可以优化和定制我们的标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。
制药连续制造市场:
Pharmaceutical Continuous Manufacturing Market: Strategic Insights
Pharmaceutical Continuous Manufacturing Market
-
CAGR (2023 - 2031)
10.6%
-
Market Size 2023
US$ 2.08 Billion
-
Market Size 2031
US$ 4.67 Billion
Key Players
- GEA Group
- Coperion GmbH
- Gericke AG
- Glatt GmbH
- Hosokawa Micron Group
- Munson Machinery Co Inc
- Powrex Corp
- Thermo Fisher Scientific Inc
- Freund vector Corporation
- Fette Compacting
Regional Overview
- 北美(美国、加拿大、墨西哥)
- 欧洲(英国、德国、法国、俄罗斯、意大利、欧洲其他地区)
- 亚太地区(中国、印度、日本、澳大利亚、亚太地区其他地区)
- 南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
- 中东和非洲(南非、沙特阿拉伯、阿联酋、中东和非洲其他地区)
Market Segmentation
产品(集成系统、半连续系统、控制)
应用(最终产品制造、API 制造)
最终用户(大型制造公司、研发部门)
Pharmaceutical Continuous Manufacturing Market: Strategic Insights
-
CAGR (2023 - 2031)10.6% -
Market Size 2023
US$ 2.08 Billion -
Market Size 2031
US$ 4.67 Billion
Key Players
- GEA Group
- Coperion GmbH
- Gericke AG
- Glatt GmbH
- Hosokawa Micron Group
- Munson Machinery Co Inc
- Powrex Corp
- Thermo Fisher Scientific Inc
- Freund vector Corporation
- Fette Compacting
Regional Overview
- 北美(美国、加拿大、墨西哥)
- 欧洲(英国、德国、法国、俄罗斯、意大利、欧洲其他地区)
- 亚太地区(中国、印度、日本、澳大利亚、亚太地区其他地区)
- 南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
- 中东和非洲(南非、沙特阿拉伯、阿联酋、中东和非洲其他地区)
Market Segmentation
年均复合增长率(2023 - 2031) (2023 - 2031)10.6%- 2023 年市场规模
20.8 亿美元 - 2031 年市场规模
46.7 亿美元
市场动态
- 药品短缺日益严重
- 连续制造工艺的优势
- 高资本投资
- 新兴市场提供高潜力增长机会
关键人物;主力;重要一员
- GEA 集团
- 科倍隆有限公司
- 格律克公司
- 格拉特有限公司
- 细川微米集团
- 蒙森机械有限公司
- 普雷克斯公司
- 赛默飞世尔科技公司
- 弗罗因德矢量公司
- 菲特压实
区域概况
- 北美
- 欧洲
- 亚太
- 南美洲和中美洲
- 中东和非洲
市场细分
- 集成系统
- 半连续系统
- 控制
- 最终产品制造
- 原料药制造
- 全面的制造公司
- 研发部门
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
制药连续制造市场驱动因素和机遇
连续制造工艺的优势有利于市场
由于对生物制剂和灵活制造替代方案的需求不断增长,制药连续制造正在受到欢迎并变得越来越重要。正在过渡到连续生产程序的公司正在迅速获得 FDA 的批准。连续制造工艺具有许多优势,包括时间效率、减少能源需求和浪费以及提高生产率。此外,由于很少有人参与制造过程,因此该过程降低了人为错误的风险。因此,由于连续制造提供的上述优势,预计市场在未来几年将会增长。
新兴市场提供高潜力增长机会
亚太地区、中南地区等地区正在出现具有吸引力的生物制药行业外包地点。中国和印度的制造和运营成本较低,这是推动亚太地区市场增长的重要因素。由于近期两国生物制药行业的增长,中国和印度都对市场未来前景表示乐观。 2020年1月,药明康德子公司合全药业有限公司在中国开设了一家新的大型寡核苷酸活性药物成分(API)生产工厂。因此,适合生物制药行业的新兴市场很可能成为药品连续制造市场的高潜力增长和收入来源。
制药连续制造市场报告细分分析
有助于药品连续制造市场分析的关键部分是产品、应用和最终用户。
- 根据产品,制药连续制造市场分为集成系统、半连续系统和控制系统。集成系统细分市场在 2023 年占据最大的市场份额,预计在预测期内复合年增长率最高。
- 按应用划分,市场分为最终产品制造和原料药制造。最终产品制造部门进一步分为固体剂型制造和液体剂型制造。最终产品制造领域在 2023 年占据最大市场份额。然而,API 制造领域预计在 2021 年至 2031 年期间复合年增长率最高。
- 根据最终用户,药品连续制造市场分为大型制造公司和研发部门。到 2023 年,全规模制造领域占据最大的市场份额,预计在预测期内复合年增长率最高。
按地域划分的制药连续制造市场份额分析
药品连续制造市场报告的地理范围主要分为五个区域:北美、亚太地区、欧洲、中东和非洲以及南美洲和中美洲。
北美主导了药品连续制造市场。导致北美药品连续生产市场增长的因素是FDA对促进连续生产而非批量生产的支持不断增加、该地区药品短缺的加剧以及有能力承担的制药巨头的存在。建立连续制造流程的大量初始投资。几十年来,美国的大多数行业都采用了连续制造工艺。由于越来越多的制药企业采用连续生产程序、制造技术领域的进步以及这些机构为扩大产量而提供的效率等因素,美国在北美占据主导地位。此外,美国 FDA 还采取了各种举措来促进美国制药行业的连续生产。
制药连续制造市场报告范围
报告属性 | 细节 |
---|---|
2023年市场规模 | 20.8亿美元 |
2031 年市场规模 | 46.7亿美元 |
全球复合年增长率(2023 - 2031) | 10.6% |
历史数据 | 2021-2022 |
预测期 | 2024-2031 |
涵盖的细分市场 | 按产品分类
|
覆盖地区和国家 | 北美
|
市场领导者和主要公司简介 |
|
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
制药连续制造市场新闻和最新动态
制药连续制造市场是通过收集初级和二级研究后的定性和定量数据来评估的,其中包括重要的公司出版物、协会数据和数据库。下面列出了药品连续制造市场的一些发展:
- 韩国合同开发和制造组织 (CDMO) SK Bioscience 位于韩国庆尚北道安东市的 L House 疫苗生产设施扩建项目已破土动工,占地约 4,200 平方米,该设施将作为肺炎球菌结合物的生产基地候选疫苗 GBP410 由 SK Bioscience 和赛诺菲联合开发,并共同投资扩建。 (SK Bioscience,新闻稿,2024 年 3 月)
- 美国基本药物公益公司 Phlow Corp. 宣布与弗吉尼亚联邦大学 (VCU) Medicines for All Institute 和 AMPAC Fine Chemicals 建立战略联盟,为小分子药品提供合同连续制造研发 (R&D) 服务。除了强大且不断增长的内部能力外,Phlow 的成熟、创新和经验丰富的战略合作伙伴网络还将为小分子活性药物成分 (API) 和注册起始原料 (RSM) 提供高质量、基于美国的先进制造解决方案。使用最先进的技术和独特的行业见解的发展阶段。 (Phlow Corp.,新闻,2022 年 3 月)
制药连续制造市场报告范围和可交付成果
《制药连续制造市场规模和预测(2021-2031)》报告对涵盖以下领域的市场进行了详细分析:
- 药品连续制造市场规模以及全球、区域和国家层面涵盖的所有关键细分市场的预测
- 制药连续制造市场趋势以及市场动态,例如驱动因素、限制因素和关键机遇
- 详细的 PEST 和 SWOT 分析
- 制药连续制造市场分析,涵盖主要市场趋势、全球和区域框架、主要参与者、法规和最新市场发展
- 行业格局和竞争分析,包括市场集中度、热图分析、知名参与者以及制药连续制造市场的最新发展
- 详细的公司简介
Pharmaceutical Continuous Manufacturing Market Report Scope
Report Attribute | Details |
---|---|
Market size in | US$ 2.08 Billion |
Market Size by | US$ 4.67 Billion |
Global CAGR | 10.6% |
Historical Data | 2021-2022 |
Forecast period | 2024-2031 |
Segments Covered |
By 产品(集成系统、半连续系统、控制) |
Regions and Countries Covered |
北美(美国、加拿大、墨西哥)
|
Market leaders and key company profiles |
|
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The North America region dominated the pharmaceutical continuous manufacturing market in 2023.
Increasing shortage of medicines, and advantages offered by continuous manufacturing process are the driving factors impacting the pharmaceutical continuous manufacturing market.
Growing support from regulatory bodies, rising adoption by contract and in-house manufacturers for drug manufacturing procedures, and advantages associated with continuous manufacturing are likely to act as future trends for the pharmaceutical continuous manufacturing market.
GEA Group and Thermo Fisher Scientific Inc. are the leading players operating in the pharmaceutical continuous manufacturing market.
US$ 4.67 billion would be the estimated value of the pharmaceutical continuous manufacturing market by 2031.
10.6% is the CAGR of the pharmaceutical continuous manufacturing market.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.